Abstract
Based on the notion that cerebral accumulation of certain Aβ species is central to AD pathogenesis and endowed with the knowledge that emerged during clinical testing of the first human Alzheimer vaccine, AN1792, we designed a new generation of Alzheimer vaccines. Rather than relying on full-length Aβ itself or fragments thereof, AFFITOPE vaccines use short peptides, mimicking parts of the native Aβ sequence, as their antigenic component. The technology created to identify these peptides, termed AFFITOPE-technology, at the same time provides the basis for the multi-component safety concept realized in AFFITOPE vaccines. First, as they are non-self, AFFITOPES don’t need to break tolerance typically established against self proteins. This allows us to use aluminium hydroxide, the agent first approved as immunological adjuvant for human use and, thus, exhibiting an excellent safety profile. Second, AFFITOPES employed in Alzheimer vaccines are only 6 amino acids in length, which precludes the activation of Aβ-specific autoreactive T cells. Third, and above all, the AFFITOPE technology allows for controlling the specificity of the vaccine-induced antibody response focusing it exclusively on Aβ and preventing crossreactivity with APP. In a program based on two AFFITOPES allowing neoepitope targeting of Aβ (free N-terminus), this approach was taken all the way from concept to clinical application. Early clinical data support the safety concept inherent to AFFITOPE Alzheimer vaccines. Further clinical testing will focus on the identification of the optimal vaccine dose and immunization schedule. Together, result of these trials will provide a solid basis for clinical POC studies.
Similar content being viewed by others
Abbreviations
- Aa:
-
amino acid
- Aβ:
-
amyloid β
- Ab:
-
antibody
- AD:
-
Alzheimer’s disease
- AD:
-
adverse event
- APP:
-
Amyloid Precursor Protein
- BBB:
-
blood brain barrier
- CMI:
-
cell mediated immunity
- FDA:
-
Federal Drug Agency
- IFN:
-
Interferon
- ME:
-
meningoencephalitis
- NINCDS/ADRDA:
-
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria
- POC:
-
Proof of concept
- SUSAR:
-
suspected unexpected serious adverse reaction
References
Schenk, D., R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, and P. Seubert. 1999. Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177.
Janus, C., J. Pearson, J. McLaurin, P. M. Mathews, Y. Jiang, S. D. Schmidt, M. A. Chishti, P. Horne, D. Heslin, J. French, H. T. Mount, R. A. Nixon, M. Mercken, C. Bergeron, P. E. Fraser, P. St George-Hyslop, and D. Westaway. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408:979–982.
Sigurdsson, E. M., H. Scholtzova, P. D. Mehta, B. Frangione, and T. Wisniewski. 2001. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer’s disease-associated pathology in transgenic mice. Am J Pathol 159:439–447.
Wilcock, D. M., G. DiCarlo, D. Henderson, J. Jackson, K. Clarke, K. E. Ugen, M. N. Gordon, and D. Morgan. 2003. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23:3745–3751.
Morgan, D., D. M. Diamond, P. E. Gottschall, K. E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Hatcher, C. Hope, M. Gordon, and G. W. Arendash. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408:982–985.
Orgogozo, J. M., S. Gilman, J. F. Dartigues, B. Laurent, M. Puel, L. C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B. F. Michel, M. Boada, A. Frank, and C. Hock. 2003. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46–54.
Vitaliani, R., M. Zoccarato, M. Vianello, and B. Giometto. 2008. Clinical, immunological and therapeutic aspects of autoimmune encephalitis. Recent Patents CNS Drug Discov 3:16–22.
Gilman, S., M. Koller, R. S. Black, L. Jenkins, S. G. Griffith, N. C. Fox, L. Eisner, L. Kirby, M. B. Rovira, F. Forette, and J. M. Orgogozo. 2005. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562.
Grundman, M. 2008. 10th International Springfield Symposium, Hong Kong.
Nicoll, J. A., D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448–452.
Ferrer, I., M. Boada Rovira, M. L. Sanchez Guerra, M. J. Rey, and F. Costa-Jussa. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol 14:11–20.
Masliah, E., L. Hansen, A. Adame, L. Crews, F. Bard, C. Lee, P. Seubert, D. Games, L. Kirby, and D. Schenk. 2005. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129–131.
Holmes, C., D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, A. Bayer, R. W. Jones, R. Bullock, S. Love, J. W. Neal, E. Zotova, and J. A. Nicoll. 2008. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223.
Le Poole, I. C., and R. M. Luiten. 2008. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun 10:227–243.
Rudolph. 2006. How TCRs bind MHCs, peptides and coreceptors. Ann Review Immunol 24:419–466.
Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133:775–787.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schneeberger, A., Mandler, M., Otava, O. et al. Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing. J Nutr Health Aging 13, 264–267 (2009). https://doi.org/10.1007/s12603-009-0070-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-009-0070-5